Global Cord Blood Corporation (CO) |
|
2.9876 0 (0%)
|
03-24 09:31 |
|
Open: |
2.21 |
Pre. Close: |
2.9876 |
|
High:
|
3.32 |
Low:
|
2.21 |
|
Volume:
|
7 |
Market Cap:
|
400(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:24:58 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 3.87 One year: 4.52 |
| Support: |
Support1: 2.63 Support2: 2.21 |
| Resistance: |
Resistance1: 3.31 Resistance2: 3.87 |
| Pivot: |
2.98  |
| Moving Average: |
MA(5): 2.98 MA(20): 2.98
MA(100): 2.98 MA(250): 2.89 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 70  %D(3): 69.9 |
| RSI: |
RSI(14): 5.8 |
| 52-week: |
High: 4 Low: 2.02 |
| Average Vol(K): |
3-Month: 0 (K) 10-Days: 0 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CO ] has closed above bottom band by 19.4%. Bollinger Bands are 1947.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.32 - 3.34 |
3.34 - 3.35 |
|
Low:
|
2.18 - 2.2 |
2.2 - 2.21 |
|
Close:
|
2.96 - 2.99 |
2.99 - 3.01 |
|
Company Description |
|
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd. |
Headline News |
Wed, 01 Mar 2023
CytoImmune Therapeutics Appoints Yulii Bogatyrenko as Chief ... - Yahoo Finance
Mon, 26 Sep 2022
Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands - Yahoo Finance
Fri, 23 Sep 2022
The Grand Court of the Cayman Islands Granted Blue Ocean’s Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation - Yahoo Finance
Wed, 06 Jul 2022
Global Cord Blood Corporation Obtained Injunction Order Against ... - PR Newswire
Thu, 16 Jun 2022
Shareholders Led by Blue Ocean Announce Successful Results of ... - Business Wire
Fri, 03 Jun 2022
Shareholders Led by Blue Ocean Call Extraordinary General ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
134 (M) |
| Shares Float |
36 (M) |
|
% Held by Insiders
|
61.5 (%) |
|
% Held by Institutions
|
22.1 (%) |
|
Shares Short
|
1,080 (K) |
|
Shares Short P.Month
|
1,080 (K) |
Stock Financials |
|
EPS
|
0.58 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0.15 |
|
EPS Est Next Year
|
0.17 |
|
Book Value (p.s.)
|
40.13 |
|
Profit Margin (%)
|
40.2 |
|
Operating Margin (%)
|
48.9 |
|
Return on Assets (ttm)
|
4.6 |
|
Return on Equity (ttm)
|
10.9 |
|
Qtrly Rev. Growth
|
-1.8 |
|
Gross Profit (p.s.)
|
7.91 |
|
Sales Per Share
|
9.25 |
|
EBITDA (p.s.)
|
4.9 |
|
Qtrly Earnings Growth
|
-18.3 |
|
Operating Cash Flow
|
614 (M) |
|
Levered Free Cash Flow
|
379 (M) |
Stock Valuations |
|
PE Ratio
|
5.06 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.07 |
|
Price to Sales
|
0.32 |
|
Price to Cash Flow
|
0.65 |
Stock Dividends |
|
Dividend
|
0.07 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
2.6% |
|
Dividend Pay Date
|
2018-08-23 |
|
Ex-Dividend Date
|
2018-07-30 |
|
Your Ad Here
|
|
